Navigation Links
iCyt Unveils Exciting New Flow Cytometry Reagents Utilizing Innovative Fluorochrome Technology

CHAMPAIGN, Ill., April 11, 2011 /PRNewswire/ -- iCyt Mission Technology, Inc. (iCyt), a wholly-owned subsidiary of Sony Corporation of America, today announced the introduction of its new line of 405nm-excited fluorochrome conjugated antibodies for flow cytometry. These new Brilliant Violet™ 421 products are part of the first commercial release of a novel, polymer-based fluorophore technology.

"This exciting new class of fluorescent probes will make significant contributions to the future of flow cytometry, by bringing new power and utility to the violet (405nm) laser," said Gary Durack, CEO of iCyt. "The new Brilliant Violet fluors offer dramatic improvements in brightness and signal-to-noise ratio over the current choices for the violet laser."  

In addition to being an order of magnitude brighter than traditional violet excited fluorochromes, this new dye offers greater sensitivity for resolving weakly expressed antigens, and requires less compensation for spectral overlap. Their compatibility with other popular fluorochromes and fluorescent protein combinations offers versatility that will further expand researchers' options for multi-color panels.

The initial iCyt portfolio of anti-mouse and anti-human conjugates have been optimized for use with iCyt's Eclipse™ analyzer and upcoming Synergy™ benchtop sorter, but are compatible with all major commercial flow cytometers equipped with a 405nm laser.

The new BV421 line will include an extensive antibody selection that combines consistent bright staining that is effective for surface and intracellular antigens, with simple, ready-to-use, low volume test size.  The new probes are fixation stable and compatible with standard staining buffers.  

iCyt intends to continually expand its new line of BV reagents, which complement its already broad portfolio of mouse and human monoclonal antibodies tailored for use in cell biology, immunology, cancer research, and stem cell research.

"iCyt and Sony are committed to leading the way in bringing innovative, new instrument and reagent technology combinations to market, that maximize performance and value for our customers," added Durack.

About iCyt:

iCyt supplies advanced flow cytometry analysis and sorting technology for use in life science research. Its products are marketed to private and public research institutions, pharmaceutical and biotechnology companies, and large medical centers. iCyt has received significant industry recognition for its line of multi-channel, high-speed cell sorting products. iCyt, a wholly owned subsidiary of Sony Corporation of America, is headquartered in Champaign, Illinois. For more information, visit

Synergy and Eclipse are trademarks of iCyt Mission Technology, Inc. Brilliant Violet and Brilliant Violet 421 are trademarks of Sirigen Ltd.

SOURCE iCyt Mission Technology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products
2. Generex Unveils Strategic Development Plan
3. Sigma-Aldrich Unveils Dynamic New Web Presence
4. NABP Unveils Relaunch of
5. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
6. Correction: New Mexico Software Unveils Additional Software Significantly Expanding Availability of Its Telemedicine Services
7. New Mexico Software Unveils Additional Software Significantly Expanding Availability of Its Telemedicine Services
8. Troy Healthcare, LLC Acquires Stopain® Brand; Unveils New Pain Relieving Gel Set to Hit Stores in Early 2011
9. Pepex™ Unveils Development of First All-In-One Blood Glucose Meter
10. eTransX Unveils Latest Version of Its eTX HEMI
11. ERT Unveils Full Range of ePRO Solutions Providing the Power of Choice for Clinical Trial Sponsors
Post Your Comments:
(Date:12/1/2015)... -- Six months of adjunctive metformin therapy does not improve glycemic ... new research from T1D Exchange and funded by ... effect on measures of obesity, including weight and BMI. The ... of the American Medical Association , are from the largest ... overweight and obese adolescents with type 1 diabetes. ...
(Date:12/1/2015)... Russia has always been a country of choice for ... Europe in 2015 were tested in phase II-III ... has always been a country of choice for global multi-center phase ... in 2015 were tested in phase II-III clinical trials ... always been a country of choice for global multi-center phase III clinical ...
(Date:12/1/2015)... 1, 2015 Contraceptives ... Contraceptives, Male Condoms, Female Condoms, Intrauterine Devices, ... Diaphragms, Contraceptive Sponges, Non-Surgical Permanent Contraception Devices) ... Trends and Forecast 2014 - 2020 ", ... (TMR).The report states that the global contraceptives ...
Breaking Medicine Technology:
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... According ... of obesity groups has filed a discrimination claim against the U.S. Department of Health ... in their Affordable Care Act (ACA) plans are breaking the clause in the law ...
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , one of ... iconic bottle has won top honors in Beverage World Magazine’s Global Packaging Design Awards, ... that it has been selected as a 2015 U.S.A. Taste Champion in the American ...
(Date:12/1/2015)... MA (PRWEB) , ... December 01, 2015 , ... Growth ... in part due to decreases in utilization of hospital and nonhospital care, according to ... CompScope™ Medical Benchmarks for Louisiana, 16th Edition , found medical payments per claim ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today ... Golden Bridge Business Awards under the New Products and Services category for its ... sample management software that helps labs organize data and track samples ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
Breaking Medicine News(10 mins):